Investor Presentation Q1-Q3 2020
11
Investor presentation
First nine months of 2020
SaxendaⓇ sales growth of 6% is impacted by COVID-19 as fewer
patients initiated treatment
Reported sales split in operational units
Novo Nordisk remains global market leader
DKK
billion
1.6
1.2
64%
0.8
0.4
0
NAO
ΙΟ
-Market share (RHS) ☐ Growth at CER
42%1
6%2
Market
share
80%
51%1
63%
60%
Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3
2017
2018
2019
2020
40%
20%
0%
1 Annual growth at CER
2 Year-to-date growth at CER
EMEA: Europe, Middle East and Africa, NAO: North America operations, IO: International operations, RHS: Right hand side axis
Note: Sales growth at constant exchange rates
Global
ΟΙ
NAO
•
•
•
•
Novo Nordisk expands market leadership to 63%
SaxendaⓇ is now launched in 54 countries
Sales growth impacted by fewer patients initiating treatment
due to COVID-19 pandemic
•
Sales growth of 8% driven by EMEA and Rest of World
Novo Nordisk currently has a value market share of 40% in the
obesity prescription drug market
• Sales growth of 4% driven by both the USA and Canada
.
Novo Nordisk currently has a value market share of 78% in the
obesity prescription drug market
Novo Nordisk®View entire presentation